Iron deficiency anemia (IDA) is the most prevalent extra-intestinal sequelae of pediatric inflammatory bowel disease. As IV iron therapy options expand, use of oral iron supplementation (oral Fe) to treat IDA in the presence of increased ulcerative colitis (UC) disease activity is low due to beliefs of low bioavailability and effectiveness. The purpose of this study is to evaluate the effectiveness of oral Fe in anemic pediatric UC patients after hospitalization for disease flare.